Jefferies Financial Group Inc. Has $3.25 Million Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Jefferies Financial Group Inc. lowered its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 3.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 599,042 shares of the biopharmaceutical company’s stock after selling 23,431 shares during the period. Jefferies Financial Group Inc.’s holdings in Sage Therapeutics were worth $3,253,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Thrivent Financial for Lutherans raised its holdings in shares of Sage Therapeutics by 108.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 38,876 shares in the last quarter. Amundi bought a new stake in Sage Therapeutics during the 4th quarter worth $166,000. SG Americas Securities LLC grew its position in Sage Therapeutics by 57.7% during the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 8,228 shares during the last quarter. Empowered Funds LLC bought a new stake in Sage Therapeutics during the 4th quarter worth $91,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Sage Therapeutics by 157.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 169,057 shares of the biopharmaceutical company’s stock worth $918,000 after acquiring an additional 103,495 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Price Performance

Shares of NASDAQ:SAGE opened at $6.61 on Wednesday. The company has a market capitalization of $413.92 million, a price-to-earnings ratio of -1.00 and a beta of 0.20. The business’s 50-day moving average is $7.49 and its 200-day moving average is $6.74. Sage Therapeutics, Inc. has a 1 year low of $4.62 and a 1 year high of $13.47.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.02). The business had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The firm’s revenue for the quarter was up 78.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.80) earnings per share. Analysts anticipate that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SAGE shares. Scotiabank reduced their price objective on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, February 12th. Wedbush restated a “neutral” rating and set a $6.00 price objective on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Bank of America started coverage on Sage Therapeutics in a research report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price objective on the stock. Canaccord Genuity Group reduced their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, February 12th. Finally, HC Wainwright restated a “neutral” rating and set a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.81.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.